跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2016/06/007043
CTRI/2016/06/007043已完成未知

A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study of SPARC1612 and reference1612 in Subjects with Locally Recurrent or Metastatic Breast Cancer (MBC).

Sun Pharma Advanced Research Company Ltd0 个研究点目标入组 28 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
未知
状态
已完成
入组人数
28
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •The subject has given written, informed consent (or
  • •legally acceptable representative /impartial
  • •witness when applicable) and is available for the
  • •duration of study
  • •- Histologically or cytologically confirmed diagnosis of breast cancer
  • •- Locally recurrent or MBC for which taxane-based therapy is an appropriate
  • •treatment option
  • •- Male or female aged >= 18 years

排除标准

  • •- Presence of clinically symptomatic active CNS metastases
  • •- Pre-existing clinically significant peripheral neuropathy
  • •- Inability to undergo venipuncture and/or tolerate venous access
  • •- Known hypersensitivity to either of the study drugs or their excipients

研究者

相似试验

已完成
不适用
Pharmacokinetic study of SPARC1613 and Reference1613
CTRI/2016/12/007565Sun Pharma Advanced Research Company Limited142
Unknown
1 期
A Randomized, Open Label,Two Period, Single Dose Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane® in Patients with Breast Cancer
CTRI/2014/04/004528Sun Pharma Advanced Research Company Ltd72
Unknown
1 期
Bioavailability Study of Paclitaxel Injection Concentrate for Suspension in Subjects with Locally Recurrent or Metastatic Breast Cancer.
CTRI/2020/03/024065Sun Pharma Advanced Research Company Limited
已完成
不适用
Randomized, Open Label, Single-Dose, Two Period, Two Treatment, Two Sequence, Cross-over, Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety of Rabeprazole Sodium Delayed-release Capsule 20 mg in Healthy Volunteers.
CTRI/2017/07/008985Cadila Healthcare Limited12
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-period, Two-sequence Crossover Bioequivalence Study of Generic Linagliptin/Metformin Hydrochloride Tablets 2.5 mg/1000 mg and Reference Product (TRAJENTA DUO) in Healthy Thai Volunteers under Fed ConditionsBioequivalence Study Healthy Thai Volunteers
TCTR20231012008International Bio Service Co., Ltd.40